Orthocell (ASX:OCC) finalized an agreement with Marine Biomedical, increasing its equity interest to 11.7% from 1.72% for a total investment of AU$1.1 million, according to a Friday filing with the Australian bourse.
The company also secured global distribution rights to PearlBone, Marine Biomedical's bone regeneration technology, as well as its future bone repair products under the deal, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.